These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 18368303

  • 41. Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
    Gupta F, Kremens D, Vernino S, Karabin B.
    Clin Auton Res; 2017 Jul; 27(Suppl 1):9-11. PubMed ID: 28699048
    [No Abstract] [Full Text] [Related]

  • 42. Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report.
    Ho AH, Kinter CW, Wight J, Neelam AR, Krakow D.
    J Med Case Rep; 2020 Jun 20; 14(1):73. PubMed ID: 32560740
    [Abstract] [Full Text] [Related]

  • 43. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol.
    Patrick K, Martin T.
    JBI Database System Rev Implement Rep; 2017 Sep 20; 15(9):2287-2294. PubMed ID: 28902695
    [Abstract] [Full Text] [Related]

  • 44. [Clinical effects of oral L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in patients with Shy-Drager syndrome].
    Senda Y, Muto T, Matsuoka Y, Takahashi A, Sobue I.
    Rinsho Shinkeigaku; 1987 Mar 20; 27(3):300-4. PubMed ID: 3111772
    [No Abstract] [Full Text] [Related]

  • 45. Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review.
    McDonell KE, Shibao CA, Biaggioni I, Hartman A, Robertson D, Claassen DO.
    Cogn Behav Neurol; 2019 Sep 20; 32(3):179-184. PubMed ID: 31517701
    [Abstract] [Full Text] [Related]

  • 46. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD, Cilmi KM, Mattis-Graves K.
    Clin Pharmacol Ther; 1984 Sep 20; 36(3):302-6. PubMed ID: 6432398
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W, Birkmayer G, Lechner H, Riederer P.
    J Neural Transm; 1983 Sep 20; 58(3-4):305-13. PubMed ID: 6420517
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Endogenous restoration of noradrenaline by precursor therapy in dopamine-beta-hydroxylase deficiency.
    Biaggioni I, Robertson D.
    Lancet; 1987 Nov 21; 2(8569):1170-2. PubMed ID: 2890806
    [Abstract] [Full Text] [Related]

  • 53. Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension.
    Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I.
    Hypertension; 2019 Jan 21; 73(1):235-241. PubMed ID: 30571543
    [Abstract] [Full Text] [Related]

  • 54. Chemical pharmacotherapy for the treatment of orthostatic hypotension.
    Cheshire WP.
    Expert Opin Pharmacother; 2019 Feb 21; 20(2):187-199. PubMed ID: 30376728
    [Abstract] [Full Text] [Related]

  • 55. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA.
    J Med Econ; 2016 Feb 21; 19(5):515-25. PubMed ID: 26710315
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
    François C, Rowse GJ, Hewitt LA, Vo P, Hauser RA.
    BMC Neurol; 2016 Aug 18; 16(1):143. PubMed ID: 27538531
    [Abstract] [Full Text] [Related]

  • 59. Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
    Gupta F, Karabin B, Mehdirad A.
    Clin Auton Res; 2017 Jul 18; 27(Suppl 1):15-16. PubMed ID: 28699047
    [No Abstract] [Full Text] [Related]

  • 60. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.
    Kaufmann H.
    J Neural Transm Suppl; 2006 Jul 18; (70):477-84. PubMed ID: 17017570
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.